• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 11:06:54 AM ET
    $SNSS
    Major Pharmaceuticals
    Health Care
    Get the next $SNSS alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

    Sunesis Pharmaceuticals INC

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    867328700

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [  ] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [  ] Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

       
     

     

    CUSIP No. 867328700

     

    1. NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Ayrton Capital LLC
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) [  ]
    (b) [X]

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    0*

    6.

    SHARED VOTING POWER

     0

    7.

    SOLE DISPOSITIVE POWER

     

    0*

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0*

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    [  ]

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%*

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

     

     

     

    CUSIP No. 867328700

     

    1. NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) [  ]
    (b) [X]

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    0*

    6.

    SHARED VOTING POWER

     

    7.

    SOLE DISPOSITIVE POWER

     

    0*

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0*

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    [  ]

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%*

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO

     

     

     

     

    CUSIP No. 867328700

     

    1. NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Waqas Khatri
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) [  ]
    (b) [X]

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Pakistan

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    0*

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    0*

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0*

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    [  ]

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%*

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

     

     

    CUSIP No. 867328700

     

    Item 1. (a). Name of Issuer:
         
        Sunesis Pharmaceuticals, INC
         
      (b). Address of issuer’s principal executive offices:
         
        395 Oyster Point Boulevard, Suite 400
        South San Francisco, California 94080
         
    Item 2. (a). Name of person filing:
         
       

    Ayrton Capital LLC

    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B

        Waqas Khatri
         
      (b). Address or principal business office or, if none, residence:
       
        Ayrton Capital LLC
        55 Post Rd West, 2nd Floor
       

    Westport, CT 06880

     

    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B

    Suite #7, Grand Pavilion Commercial Centre

    802 West Bay Road

    Grand Cayman

    P.O. Box 10250

    KY1-1003

    Cayman Islands

         
       

    Waqas Khatri

    c/o Ayrton Capital LLC

    55 Post Rd West, 2nd Floor

    Westport, CT 06880

         
      (c). Citizenship:
         
       

    Ayrton Capital LLC – Delaware limited liability company

    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B- Cayman Islands

        Waqas Khatri – Pakistan
         
      (d). Title of class of securities:
         
        Common Stock, $0.0001 par value
         
      (e). CUSIP No.:
         
        867328700

     

    Item 3. If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a)   [_]   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
               
      (b)   [_]   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
               
      (c)   [_]   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
               
      (d)   [_]   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-
              8).
      (e)   [_]   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
               
      (f)   [_]   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
               
      (g)   [_]   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
               
      (h)   [_]   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
               
      (i)   [_]   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
               
      (j)   [_]   A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
               
      (k)   [_]   Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

     

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:

     

    Ayrton Capital LLC –0 shares*

    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B - 0 shares*

    Waqas Khatri – 0 shares*

     

      (b) Percent of class:

     

    Ayrton Capital LLC –0%*

    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B – 0%*

    Waqas Khatri – 0%*

     

      (c) Number of shares as to which Ayrton Capital LLC has:

     

      (i) Sole power to vote or to direct the vote   0* ,
               
      (ii) Shared power to vote or to direct the vote   0 ,
               
      (iii) Sole power to dispose or to direct the disposition of   0* ,
               
      (iv) Shared power to dispose or to direct the disposition of   0 .
               
      Number of shares as to which Waqas Khatri has:      
               
      (i) Sole power to vote or to direct the vote   0* ,
               
      (ii) Shared power to vote or to direct the vote   0 ,
               
      (iii) Sole power to dispose or to direct the disposition of   0* ,
               
      (iv) Shared power to dispose or to direct the disposition of   0 .
             
     

    Number of shares as to which Alto Opportunity Master Fund SPC- Segregated Master Portfolio B has:

         
               
      (i) Sole power to vote or to direct the vote   0* ,
               
      (ii) Shared power to vote or to direct the vote   0 ,
               
      (iii) Sole power to dispose or to direct the disposition of   0* ,
               
      (iv) Shared power to dispose or to direct the disposition of   0 .

     

    *Shares reported herein were held by Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (the “Fund”), a Cayman Islands exempted company (all of the foregoing, collectively, the “Reporting Persons”). The Fund is a private investment vehicle for which Ayrton Capital LLC (the “Investment Manager”) serves as the investment manager and Waqas Khatri serves as the managing member of the Investment Manager.

     

    By virtue of these relationships, the Reporting Persons may be deemed to have sole voting and dispositive power with respect to the Shares owned directly by the Fund. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the Shares for purposes of Section 13 of the Exchange Act, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of the Reporting Person’s pecuniary interest therein.

     

    The percentage ownership of each Reporting Person is based on 113,924,602 Ordinary Shares outstanding as of November 29, 2020, as reported by the Issuer Form 424B3 filed with the Securities and Exchange Commission on January 14, 2021. 

     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

    N/A

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

    N/A

     

    Item 8. Identification and Classification of Members of the Group.

     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d- 1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

     

    N/A

     

    Item 9. Notice of Dissolution of Group.

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

    N/A

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 16, 2021 Ayrton Capital LLC
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member
         
      Alto Opportunity Master Fund SPC – Segregated Master Portfolio B
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member
         
      Ayrton Capital LLC
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     

    Get the next $SNSS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SNSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by J. Barry Simon

      3 - Viracta Therapeutics, Inc. (0001061027) (Issuer)

      3/4/21 5:46:22 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 3 filed by Stephen Rubino

      3 - Viracta Therapeutics, Inc. (0001061027) (Issuer)

      3/4/21 5:42:13 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 3: Partnership Limited Fund 2 Amoon claimed ownership of 7,392,237 units of Common Stock

      3 - SUNESIS PHARMACEUTICALS INC (0001061027) (Issuer)

      2/25/21 6:09:20 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    SEC Filings

    See more
    • SEC Form 8-K filed

      8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)

      3/4/21 4:06:03 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 8-K filed

      8-K - SUNESIS PHARMACEUTICALS INC (0001061027) (Filer)

      2/24/21 4:34:51 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 10-K filed

      10-K - SUNESIS PHARMACEUTICALS INC (0001061027) (Filer)

      2/24/21 6:06:16 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

      SAN DIEGO, Feb. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082. The allowed application, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," describes the use of Viracta's all-oral combination product candidate of nanatinostat, the Company's proprietary investigational drug, and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial for the trea

      2/16/21 8:00:00 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences

      SAN DIEGO, Feb. 11, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the Company will participate in the upcoming LifeSci Partners Precision Oncology Day on February 17, 2021 and the 10th Annual SVB Leerink Global Healthcare Conference taking place February 22-26, 2021. The Company will present and participate in one-on-one investor meetings at both conferences. Details on the events can be found below. LifeSci Partners Precision Oncology Day Date: Wednesday, February 17, 2021 Time: 2:30 PM ET Format: Corporate presentation 10th Annual SVB Leerink Globa

      2/11/21 4:05:00 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA

      SAN DIEGO, Dec. 7, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent clinical and regulatory developments regarding its lead program for the treatment of relapsed/refractory (R/R) EBV+ lymphomas. At the 62nd American Society of Hematology (ASH) Annual Meeting, Dr. Pierluigi Porcu of Sidney Kimmel Cancer Center, Thomas Jefferson University, presented updated data from Viracta's ongoing clinical trial evaluating its all-oral combination regimen of nanatinostat and valganciclovir for the treatment of patients with R/R EBV+ lymphoma that had failed one or more prior therapies

      12/7/20 8:30:00 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sunesis Pharmaceuticals upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Sunesis Pharmaceuticals from Market Perform to Outperform and set a new price target of $12.00

      3/1/21 8:39:16 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • Sunesis Pharmaceuticals upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Sunesis Pharmaceuticals from Perform to Outperform and set a new price target of $12.00

      2/23/21 5:59:10 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Financials

    Live finance-specific insights

    See more
    • Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

      Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies Registration trial for Viracta’s lead program in Epstein-Barr virus (EBV)-positive lymphomas expected to begin in the first half of 2021 Leading institutional investors committed a total of $105 million in private financings with Viracta Combined company expected to have approximately $120 million cash balance following the close of the merger Companies to host conference call today at 8:30 AM Eastern Time SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) and Viracta

      11/30/20 7:30:00 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed

      SC 13D/A - Viracta Therapeutics, Inc. (0001061027) (Subject)

      3/10/21 9:40:22 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Viracta Therapeutics, Inc. (0001061027) (Subject)

      3/8/21 5:05:56 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Viracta Therapeutics, Inc. (0001061027) (Subject)

      3/5/21 1:30:27 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care